Form 4: Decheng Capital Reports Minor BYSI Share Sales

Decheng Capital, a 10% owner and director of BeyondSpring Inc., reported minor sales of ordinary shares in late August and early September 2025.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director of BeyondSpring Inc. (BYSI), reported the sale of 4,870 ordinary shares across three transactions.
• On August 29, 2025, 800 shares were sold at a weighted average price of $1.74 per share, ranging from $1.72 to $1.80.
• On September 2, 2025, 2,800 shares were sold at a weighted average price of $1.78 per share, ranging from $1.67 to $1.84.
• On September 3, 2025, 1,270 shares were sold at a weighted average price of $1.81 per share, ranging from $1.79 to $1.84.
• These transactions were not made pursuant to a Rule 10b5-1 trading plan.
• Following these sales, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,904,755 ordinary shares.
• Additionally, Decheng Capital China Life Sciences USD Fund II, L.P. beneficially owns 1,617,409 ordinary shares, and Decheng Capital Global Healthcare Fund (Master), LP beneficially owns 891,734 ordinary shares.

Sentiment

Score: 5

Explanation: Neutral. While insider selling occurred, the volume of shares sold is very small relative to Decheng Capital's total holdings and the company's market capitalization, suggesting it's likely a routine portfolio adjustment rather than a significant loss of confidence.

Negatives

• Insider selling by a 10% owner and director, Decheng Capital, which could be perceived negatively by the market.
• The sales were discretionary and not executed under a Rule 10b5-1 trading plan, which might suggest a more immediate decision to sell.

Risks

• Potential for negative market perception or misinterpretation of the insider selling, even though the volume is small.
• The discretionary nature of the sales, not being part of a pre-arranged plan, could be viewed with more scrutiny.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from the company. The reported transactions are past events from the perspective of the filing date.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the reported ranges.
• Decheng Capital Management III (Cayman), LLC, Decheng Capital Management II (Cayman), LLC, Decheng Capital Global Healthcare GP, LLC, and Dr. Cui disclaim beneficial ownership of the securities held by their respective funds, except to the extent of their proportionate pecuniary interest therein.

Industry Context

Insider transaction reports are routine disclosures in the financial industry. Sales by significant shareholders and directors are closely watched, though the impact varies greatly depending on the volume and context. For a biotechnology company like BeyondSpring Inc., such transactions are often scrutinized for signals regarding clinical trial progress or regulatory approvals, even if the volume is small.

Related Party Transactions

• Sales of ordinary shares by Decheng Capital China Life Sciences USD Fund III, L.P., which is a 10% owner and has a director relationship with BeyondSpring Inc.

Stakeholder Impact

• Shareholders might interpret the insider selling as a negative signal, although the small volume of shares sold suggests a minimal direct impact on the company's valuation or future prospects.
• The disclosure provides transparency to all stakeholders regarding insider holdings and transactions.

Next Steps

• The Reporting Person has committed to providing detailed transaction information upon request from the Issuer, security holders, or the SEC staff.

Key Dates

Recommendation

The reported insider selling by Decheng Capital is of a very small volume relative to their overall holdings and BeyondSpring Inc.'s market capitalization. While it's a discretionary sale (not under a 10b5-1 plan), the minimal amount suggests it's more likely a minor portfolio rebalancing or liquidity event rather than a signal of significant negative sentiment or a fundamental change in the company's prospects. Investors should monitor future insider activity but this specific filing does not warrant a change in investment thesis.

Keywords

BeyondSpring Inc., BYSI, Decheng Capital, Insider Selling, Form 4, Beneficial Ownership, Equity Sales, Biotechnology